Tie2-expressing monocytes (TEMs): Novel targets and vehicles of anticancer therapy?

De Palma, 2006, Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis, Biochim. Biophys. Acta, 1766, 159 Wels, 2008, Migratory neighbors and distant invaders: tumor-associated niche cells, Genes Dev., 22, 559, 10.1101/gad.1636908 Murdoch, 2008, The role of myeloid cells in the promotion of tumour angiogenesis, Nat. Rev., 8, 618, 10.1038/nrc2444 Coukos, 2007, Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer, Adv. Exp. Med. Biol., 590, 185, 10.1007/978-0-387-34814-8_13 Li, 2009, Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site, Cancer Res., 69, 338, 10.1158/0008-5472.CAN-08-1565 Shojaei, 2008, Role of myeloid cells in tumor angiogenesis and growth, Trends Cell Biol., 18, 372, 10.1016/j.tcb.2008.06.003 Sica, 2007, Altered macrophage differentiation and immune dysfunction in tumor development, J. Clin. Invest., 117, 1155, 10.1172/JCI31422 Serafini, 2006, Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression, Semin. Cancer Biol., 16, 53, 10.1016/j.semcancer.2005.07.005 Lewis, 2006, Distinct role of macrophages in different tumor microenvironments, Cancer Res., 66, 605, 10.1158/0008-5472.CAN-05-4005 Egeblad, 2008, Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy, Dis. Models Mech., 1, 155, 10.1242/dmm.000596 Wyckoff, 2007, Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors, Cancer Res., 67, 2649, 10.1158/0008-5472.CAN-06-1823 Crawford, 2009, VEGF inhibition: insights from preclinical and clinical studies, Cell Tissue Res., 335, 261, 10.1007/s00441-008-0675-8 Ferrara, 2005, Angiogenesis as a therapeutic target, Nature, 438, 967, 10.1038/nature04483 Lin, 2006, Macrophages regulate the angiogenic switch in a mouse model of breast cancer, Cancer Res., 66, 11238, 10.1158/0008-5472.CAN-06-1278 Lin, 2001, Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy, J. Exp. Med., 193, 727, 10.1084/jem.193.6.727 Lin, 2007, VEGF restores delayed tumor progression in tumors depleted of macrophages, Mol. Oncol., 1, 288, 10.1016/j.molonc.2007.10.003 Stockmann, 2008, Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis, Nature, 456, 814, 10.1038/nature07445 Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science (New York, N.Y), 307, 58, 10.1126/science.1104819 Kerbel, 2008, Tumor angiogenesis, N. Engl. J. Med., 358, 2039, 10.1056/NEJMra0706596 Shojaei, 2007, Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells, Nat. Biotechnol., 25, 911, 10.1038/nbt1323 Shojaei, 2007, Bv8 regulates myeloid-cell-dependent tumour angiogenesis, Nature, 450, 825, 10.1038/nature06348 Bergers, 2008, Modes of resistance to anti-angiogenic therapy, Nat. Rev., 8, 592, 10.1038/nrc2442 Crawford, 2009, PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment, Cancer cell, 15, 21, 10.1016/j.ccr.2008.12.004 Shaked, 2006, Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors, Science (New York, N.Y), 313, 1785, 10.1126/science.1127592 Shaked, 2008, Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents, Cancer Cell, 14, 263, 10.1016/j.ccr.2008.08.001 De Palma, 2003, Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells, Nat. Med., 9, 789, 10.1038/nm871 De Palma, 2005, Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors, Cancer Cell, 8, 211, 10.1016/j.ccr.2005.08.002 Venneri, 2007, Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer, Blood, 109, 5276, 10.1182/blood-2006-10-053504 Murdoch, 2007, Expression of Tie-2 by human monocytes and their responses to angiopoietin-2, J. Immunol., 178, 7405, 10.4049/jimmunol.178.11.7405 De Palma, 2007, Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications, Trends Immunol., 28, 545, 10.1016/j.it.2007.09.004 Du, 2008, HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion, Cancer Cell, 13, 206, 10.1016/j.ccr.2008.01.034 Pahler, 2008, Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response, Neoplasia (New York, N.Y), 10, 329, 10.1593/neo.07871 Augustin, 2009, Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system, Nat. Rev., Mol. Cell Biol., 10, 165, 10.1038/nrm2639 Hirschi, 2008, Assessing identity, phenotype, and fate of endothelial progenitor cells, Arterioscler. Thromb. Vasc. Biol., 28, 1584, 10.1161/ATVBAHA.107.155960 Timmermans, 2008, Endothelial progenitor cells: identity defined?, J. Cell. Mol. Med., 10.1111/j.1582-4934.2008.00598.x Nasarre, 2009, Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth, Cancer Res., 69, 1324, 10.1158/0008-5472.CAN-08-3030 Fiedler, 2004, The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel–Palade bodies, Blood, 103, 4150, 10.1182/blood-2003-10-3685 Auffray, 2009, Blood monocytes: development, heterogeneity, and relationship with dendritic cells, Annu. Rev. Immunol., 10.1146/annurev.immunol.021908.132557 Auffray, 2007, Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior, Science (New York, N.Y, 317, 666, 10.1126/science.1142883 Lewis, 2007, Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2, Cancer Res., 67, 8429, 10.1158/0008-5472.CAN-07-1684 Holash, 1999, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science (New York, N.Y, 284, 1994, 10.1126/science.284.5422.1994 Modarai, 2005, Endothelial progenitor cells are recruited into resolving venous thrombi, Circulation, 111, 2645, 10.1161/CIRCULATIONAHA.104.492678 Shahrara, 2002, Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue, Arthritis Res., 4, 201, 10.1186/ar407 Barrette, 2008, Requirement of myeloid cells for axon regeneration, J. Neurosci., 28, 9363, 10.1523/JNEUROSCI.1447-08.2008 Jeong, 2009, Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy, Circulation, 119, 699, 10.1161/CIRCULATIONAHA.108.789297 Naldini, 1996, In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector, Science (New York, N.Y.), 272, 263, 10.1126/science.272.5259.263 Kay, 2001, Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics, Nat. Med., 7, 33, 10.1038/83324 De Palma, 2002, Transduction of a gene expression cassette using advanced generation lentiviral vectors, Methods Enzymol., 346, 514, 10.1016/S0076-6879(02)46074-0 De Palma, 2003, In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors, Hum. Gene Ther., 14, 1193, 10.1089/104303403322168028 Vigna, 2005, Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector, Molec. Ther., 11, 763, 10.1016/j.ymthe.2004.11.017 Brown, 2007, Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state, Nat. Biotechnol., 25, 1457, 10.1038/nbt1372 Gentner, 2009, Stable knockdown of microRNA in vivo by lentiviral vectors, Nat. Methods, 6, 63, 10.1038/nmeth.1277 Stark, 1998, How cells respond to interferons, Annu. Rev. Biochem., 67, 227, 10.1146/annurev.biochem.67.1.227 Stetson, 2006, Type I interferons in host defense, Immunity, 25, 373, 10.1016/j.immuni.2006.08.007 De Palma, 2008, Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis, Cancer Cell, 14, 299, 10.1016/j.ccr.2008.09.004 Parmar, 2003, Interferons: mechanisms of action and clinical applications, Curr. Opin. Oncol., 15, 431, 10.1097/00001622-200311000-00005 Belardelli, 2002, Interferon-alpha in tumor immunity and immunotherapy, Cytokine Growth Factor Rev., 13, 119, 10.1016/S1359-6101(01)00022-3 Curnis, 2005, Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms, Cancer Res., 65, 2906, 10.1158/0008-5472.CAN-04-4282 Arai, 2004, Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche, Cell, 118, 149, 10.1016/j.cell.2004.07.004 Honda, 2005, IRF-7 is the master regulator of type-I interferon-dependent immune responses, Nature, 434, 772, 10.1038/nature03464 Ljungman, 2006, Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe, Bone Marrow Transplant., 37, 439, 10.1038/sj.bmt.1705265 Aboody, 2008, Stem and progenitor cell-mediated tumor selective gene therapy, Gene Ther., 15, 739, 10.1038/gt.2008.41 Lewis, 2005, Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies, Am. J. Pathol., 167, 627, 10.1016/S0002-9440(10)62038-X Webb, 2007, Macrophage-based anti-cancer therapy: modelling different modes of tumour targeting, Bull. Math. Biol., 69, 1747, 10.1007/s11538-006-9189-2 Essers, 2009, IFNalpha activates dormant haematopoietic stem cells in vivo, Nature, 458, 904, 10.1038/nature07815